Fosamax and Osteonecrosis of the Jaw: Understanding the Biological Plausibility

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Focused Risk Assessment

The legacy of general health and science communication has long emphasized the importance of informed decision-making regarding medications and their potential impacts on overall well-being. Within this tradition, discussions of bone health and the management of conditions like osteoporosis have been framed in terms of balancing therapeutic benefits against possible adverse effects. This broad educational approach has served to empower individuals with knowledge about the substances they may encounter in their daily lives, from nutritional supplements to prescription drugs. As this informational heritage evolves, a natural progression involves examining how specific pharmaceutical exposures, particularly those occurring in controlled therapeutic settings, may carry distinct risk profiles that warrant closer scrutiny. The transition from general health awareness to a more focused occupational concern becomes apparent when considering the environments where such exposures are most concentrated and prolonged. In clinical and manufacturing contexts, personnel may handle or administer medications with greater frequency and at higher cumulative doses than typical patients. This shift in perspective moves the discussion from population-level health guidance toward a more targeted consideration of workplace safety protocols. The same principles of informed consent and risk communication that underpin general health education now apply to professional settings where exposure patterns differ markedly from the general public's experience.

Fosamax and Osteonecrosis of the Jaw: A Bridge from General Risk to Specific Harm

Building on the foundation of general health awareness, we now turn to a specific adverse event associated with the bisphosphonate medication Fosamax (alendronate): osteonecrosis of the jaw (ONJ). Fosamax is approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. While this effect is beneficial for increasing bone mass and reducing fracture risk, it has been associated with a rare but serious adverse event: osteonecrosis of the jaw. ONJ is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring after tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal after dental procedures. Diagnosis is based on clinical examination and imaging, with the hallmark being persistent bone exposure for more than eight weeks in the absence of radiation therapy or metastatic disease.

Biological Plausibility: How Fosamax May Cause Osteonecrosis of the Jaw

The biological plausibility linking Fosamax to ONJ is supported by several mechanistic pathways. Bisphosphonates, including alendronate, accumulate in bone tissue and suppress osteoclast-mediated bone remodeling. The jawbone has a high rate of bone turnover due to constant mechanical stress from chewing and the presence of teeth, making it particularly susceptible to the effects of reduced remodeling. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research indicates that bisphosphonate treatment alters the mechanical stability of teeth in the alveolar socket and changes tissue mineral density distribution and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These changes can impair the jawbone's ability to repair microdamage and respond to local infections or trauma, such as tooth extraction. Known risk factors for ONJ in patients taking bisphosphonates include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Clinical Evidence and Causation Considerations

The time to onset of symptoms after starting Fosamax can vary widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates the establishment of a clear timeline between exposure and documented harm. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that ONJ is a rare event that may not have been fully captured in premarketing trials. Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as rechallenge can reproduce the adverse effect. Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (Section 5.4) that describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label advises discontinuation of bisphosphonate treatment for patients requiring invasive dental procedures to reduce the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that the optimal duration of use has not been determined and that for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while warnings exist, the rare and delayed nature of ONJ may make it difficult for patients and clinicians to fully appreciate the risk, especially given the benefits of fracture reduction. For affected patients, causation considerations include the presence of known risk factors, the timing of symptom onset relative to drug initiation, and the exclusion of other causes such as radiation therapy or metastatic disease. The biological plausibility, supported by mechanistic studies showing altered jawbone properties with bisphosphonate treatment (https://pubmed.ncbi.nlm.nih.gov/40345077/), strengthens the argument for a causal link. However, the rarity of ONJ and the variability in onset time mean that individual cases must be evaluated on their own merits, taking into account the patient's dental history, concomitant medications, and duration of Fosamax use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological mechanism by which Fosamax may cause osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits bone resorption by osteoclasts, reducing bone turnover. The jawbone has a high rate of turnover due to mechanical stress, making it susceptible. Bisphosphonates accumulate in bone and suppress remodeling, impairing repair of microdamage and response to infection or trauma. Studies show altered mechanical stability of teeth and changes in tissue mineral density and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the known risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is osteonecrosis of the jaw diagnosed and what is the typical timeline for symptom onset?

Diagnosis is based on clinical examination and imaging, with persistent bone exposure for more than eight weeks in the absence of radiation therapy or metastatic disease. Symptom onset after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.